{'fraction_non_alphanumeric': 0.03648648648648649, 'fraction_numerical': 0.012162162162162163, 'mean_word_length': 6.194174757281553, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Valproic Acid Reduces Neuritic Plaque Formation and Improves Learning Deficits in APPSwe/PS1A246E Transgenic Mice via Preventing the Prenatal Hypoxia‐Induced Down‐Regulation of Neprilysin

Previously, we have documented that prenatal hypoxia can aggravate the cognitive impairment and Alzheimer's disease (AD) neuropathology in APPSwe/PS1A246E (APP/PS1) transgenic mice, and valproic acid (VPA) can prevent hypoxia‐induced down‐regulation of β‐amyloid (Aβ) degradation enzyme neprilysin (NEP) in primary neurons. In this study, we have investigated the molecular mechanisms of VPA's anti‐AD effects and found that VPA can reduce the prenatal hypoxia‐induced neuritic plaque formation and improve the learning deficits in the AD mouse model.